On Tuesday, American Enterprise Institute resident fellow and MGA founder and CEO Alex Brill testified before the Senate Health, Education, Labor & Pensions (HELP) Subcommittee on Primary Health and Retirement Security. The topic of the hearing was the skyrocketing prices of prescription drugs.
Much of the public debate over climate change policy focuses on the cost of reducing emissions, deploying green energy, or building adaptations. A point often lost is that whatever we do, we pay for climate change, even if we do nothing. For officials to arrive at effective solutions, they must know both the cost of the policy options and the cost of inaction.